Glynn Weldon Gilcrease
Rating: 4.9 of 5
( out of 183 reviews )

Glynn Weldon Gilcrease, MD

Languages spoken: Spanish, English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
1950 Circle of Hope
Salt Lake City , UT 84112
801-646-4365
Get Directions

  • Dr. G. Weldon Gilcrease, MD is an Associate Professor in the Oncology Division at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI) investigator. He specializes in gastrointestinal cancers and patients enrolled in early phase trials. Dr. Gilcrease is also the Program Director for the Hematology/Oncology Fellowship program at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI).

    Dr. Gilcrease focuses on early phase clinical trials and drug development. He is involved in preclinical research and Phase I/II trials for patients affected with inoperable colorectal cancer. His research entails exploiting important pathways that drive cancer, including the beta-catenin pathway in colorectal cancer. He hopes to bring novel and targeted therapies into the clinic to benefit patients.

    Dr. Gilcrease has been at the University of Utah since 2009. He completed a hematology/oncology fellowship at the University of Utah and HCI where he was awarded the Outstanding Fellow Teaching Award in 2011. Prior to that he completed his residency at Scripps Mercy Hospital in San Diego, CA where he received the Outstanding Resident Award for his medical care and dedication to learning and teaching. He served as Chief Resident after completing his residency. He earned his medical degree from the University of Arizona.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 183 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very knowledgable. Very personable. Gave detailed discussion on future treatment and testing plans.

    FARMINGTON HEALTH CENTER
    Rating: 5 out of 5

    VERY CARING AND PERSONABLE. A WONDERFUL DOCTOR WITH A SENCE OF HUMOR AND EXTREMELY KNOWLEDGEABLE.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Glynn Gilcrease is a very caring oncologist. If there are issues that need resolve. He'll stop treatment until issues are resolved. He's very engaged and personal in his patients.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    They were very informative, attentive, and answered all questions. Very friendly.

    FARMINGTON HEALTH CENTER
    Rating: 4 out of 5

    Listens well, offers different treatment options and lets you do what you think is the best treatment for you even if it means no treatment as in my case.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Gilcrease is very professional while being friendly and courteous. He is easy to talk to and listens attentively

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    ok I guess, do not remember.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Great doctor!!

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Awesome

  • Dr. G. Weldon Gilcrease, MD is an Associate Professor in the Oncology Division at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI) investigator. He specializes in gastrointestinal cancers and patients enrolled in early phase trials. Dr. Gilcrease is also the Program Director for the Hematology/Oncology Fellowship program at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI).

    Dr. Gilcrease focuses on early phase clinical trials and drug development. He is involved in preclinical research and Phase I/II trials for patients affected with inoperable colorectal cancer. His research entails exploiting important pathways that drive cancer, including the beta-catenin pathway in colorectal cancer. He hopes to bring novel and targeted therapies into the clinic to benefit patients.

    Dr. Gilcrease has been at the University of Utah since 2009. He completed a hematology/oncology fellowship at the University of Utah and HCI where he was awarded the Outstanding Fellow Teaching Award in 2011. Prior to that he completed his residency at Scripps Mercy Hospital in San Diego, CA where he received the Outstanding Resident Award for his medical care and dedication to learning and teaching. He served as Chief Resident after completing his residency. He earned his medical degree from the University of Arizona.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Education history

    Undergraduate Mathematics & Computer Science, Summa Cum Laude with Honors: Honors Thesis in Mathematics Titled Young Tableaux and Semi-Invariance of Symmetric Groups - The University of Arizona, Tucson B.S.
    Undergraduate Spanish, Summa Cum Laude - The University of Arizona, Tucson B.A.
    Professional Medical Medicine - The University of Arizona College of Medicine M.D.
    Internship/Residency Scripps Mercy Hospital Intern/Resident
    Chief Resident Scripps Mercy Hospital Chief Medical Resident
    Fellowship Hematology and Oncology - University of Utah Fellow
    Fellowship Arizona Center for Integrative Medicine Fellow

    Selected Publications

    Journal Article

    1. Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW 3rd, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M (2019). Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. Am J Clin Oncol, 42(4), 355-362. (Read full publication)
    2. Kimura BJ, Gilcrease GW 3rd, Showalter BK, Phan JN, Wolfson (2012). Diagnostic performance of a pocket-sized ultrasound device for quick-look cardiac imaging. The American journal of emergency medicine, 30(1), 32-6. (Read full publication)
    3. Gilcrease GW, Stein J (2010). A delayed case of fatal atrioesophageal fistula following radiofrequency ablation for atrial fibrillation. Journal of cardiovascular electrophysiology, 21(6), 708-11. (Read full publication)
    4. Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Investigational new drugs, 31(5), 1257-64. (Read full publication)
    5. Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma (2019). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Investigational new drugs, 37(3), 482-489. (Read full publication)
    6. Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma (2015). Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime ß-Catenin Pathway Inhibitors. Journal of medicinal chemistry, 58(15), 5854-62. (Read full publication)
    7. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2019). Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 25(4), 620-627. (Read full publication)
    8. Kimura BJ, Dalugdugan R, Gilcrease GW 3rd, Phan JN, Showalter BK, Wolfson (2011). The effect of breathing manner on inferior vena caval diameter. European journal of echocardiography, 12(2), 120-3. (Read full publication)
    9. Wells SM, Boothe D, Ager BJ, Tao R, Gilcrease GW 3rd, Lloyd (2020). Analysis of Nonsurgical Treatment Options for Metastatic Rectal Cancer. Clinical colorectal cancer, 19(2), 91-99.e1. (Read full publication)
    10. Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA, National Comprehensive Cancer Network (2014). Occult primary, version 3.2014. Journal of the National Comprehensive Cancer Network, 12(7), 969-74. (Read full publication)
    11. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. Journal of the National Comprehensive Cancer Network, 19(5), 478-482. (Read full publication)
    12. Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Akerley W, Gilcrease G, Ulrich CM, Burt RW, Curtin (2016). Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA oncology, 2(3), 340-346.
    13. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO open, 4(4), e000539. (Read full publication)
    14. Martin DB, Stetson PD, Gilcrease GW, Stillman RC, Sugalski JM, Skinner J, Levy (2021). Preferences in Oncology History Documentation Styles Among Clinical Practitioners. JCO oncology practice, 18(1), OP2000756. (Read full publication)
    15. Martin DB, Stetson PD, Gilcrease GW, Stillman RC, Sugalski JM, Skinner J, Levy (2022). Preferences in Oncology History Documentation Styles Among Clinical Practitioners. JCO oncology practice, 18(1), e1-e8. (Read full publication)
    16. Pauley K, Koptiuch C, Greenberg S, Kohlmann W, Jeter J, Colonna S, Werner T, Kinsey C, Gilcrease G, Weis J, Whisenant J, Florou V, Garrido-Laguna (2022). Discrepancies between tumor genomic profiling and germline genetic testing. ESMO open, 7(4), 100526. (Read full publication)
    17. Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes, 16(1), 16. (Read full publication)
    18. Geranios KC, Littau MJ, Park SS, Baker TB, Gilcrease GW, Cizman Z, Smith T, Baker M (2025). Localized hepatocellular carcinoma: Is liver-directed therapy alone as efficacious as surgical resection?. Surgery, 179, 108939. (Read full publication)

    Case Report

    1. Nelson KL, Stenehjem D, Driscoll M, Gilcrease G (2017). Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib. Frontiers in oncology, 7, 150. (Read full publication)

    Other

    1. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2019). Publisher Correction: Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 25(5), 861. (Read full publication)
    2. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2025). Author Correction: Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 31(6), 2069. (Read full publication)